Imaging systems maker Lumicell Diagnostics amended a previously closed $1 million funding round after landing another $560,000 in financing from 2 new investors, regulatory filings show.
Lumicell noted 7 unnamed investors who participated in the round, which was launched in December 2013. The Massachusetts company had closed the round in January after raising just over $1 million from 5 investors, but filed an amendment late in February to note the additional funding.
Wellesley, Mass.-based Lumicell is developing a combination hand-held single-cell detection device and imaging agent that aims to provide surgeons a better view of cancer cells in real time during tumor removal surgeries.
"Lumicell is addressing the number one challenge in cancer surgery – the need to remove all cancer cells during the 1st surgery within the tumor bed. In the field of cancer surgery, the goal is clean margins," according to the company’s website. "With this system, surgeons have the unprecedented ability to remove all cancer cells during an initial surgery eliminating the need for repeat surgeries."
Chris Walker contributed to this report.
